Nve Corp /New/ (NVEC) Stock Price & Analysis
Nve Corp /New/ (NVEC) fell 12.41% to USD 117.55 as of July 25, 2026 at 01:45 UTC, according to Nexqual real-time market data.
NVEC last closed at USD 134.21; the session ranged USD 112.31–135 on volume of 511,971 shares. Market capitalization is $568.61M, with a 52-week range of USD 57.21–135 (NCM). Source: Nexqual, July 25, 2026 at 01:45 UTC.
Key Statistics (as of July 25, 2026 at 01:45 UTC)
| Price | USD 117.55 |
|---|---|
| Change | ▼ 12.41% (down) |
| Previous Close | USD 134.21 |
| Open | USD 133.14 |
| Day Range | USD 112.31 – 135 |
| 52-Week Range | USD 57.21 – 135 |
| Volume | 511,971 shares |
| Market Cap | $568.61M |
| Exchange | NCM |
Technical Analysis (NVEC)
Nexqual's technical model rates NVEC "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 01:45 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.66 (neutral) |
| vs SMA50 | Above (USD 98.55) |
| MACD | 1.9 (positive) |
Analyst Ratings (NVEC)
Wall Street analysts rate NVEC "None", per Nexqual as of July 25, 2026 at 01:45 UTC.
| Consensus Rating | None |
|---|
Earnings (NVEC)
| Next Earnings Date | 2026-10-21 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2017-09-30 | USD 0.65 vs est 0.61 ▲ beat |
| 2017-06-30 | USD 0.68 vs est 0.66 ▲ beat |
| 2017-03-31 | USD 0.62 vs est 0.71 ▼ miss |
Source: Nexqual, July 25, 2026 at 01:45 UTC.
Financials & Fundamentals (NVEC)
| Total Revenue | $31.26M |
|---|---|
| Revenue Growth (YoY) | +80.70% |
| Gross Margin | +79.26% |
| Operating Margin | +65.85% |
| Profit Margin | +57.64% |
| ROE | +29.81% |
| Debt / Equity | 1.52 |
| Current Ratio | 23.72 |
| Total Cash | $21.77M |
| Total Debt | $905,825 |
| Free Cash Flow | $7.81M |
Source: Nexqual, July 25, 2026 at 01:45 UTC.
Financial Health Score (NVEC)
Nexqual rates Nve Corp /New/'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 01:45 UTC.
| Growth | Mixed — Revenue +2.2% YoY (annual), slow |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Strong — $22M cash, no debt |
| Cash Flow | Strong — FCF $8M, 28% margin |
| Efficiency | Strong — ROE 30%, ROA 19.3% |
Ownership (NVEC)
| Insider Ownership | +1.28% |
|---|---|
| Institutional Ownership | +89.47% |
| Shares Outstanding | 4.84M |
| Float | 4.78M |
| Short % of Float | +10.97% |
Source: Nexqual, July 25, 2026 at 01:45 UTC.
Leadership (NVEC)
Nve Corp /New/ is led by Daniel A. Baker (age 67), CEO, President & Director, per Nexqual as of July 25, 2026 at 01:45 UTC.
| CEO, President & Director | Daniel A. Baker (age 67) |
|---|---|
| Vice President of Advanced Technology | Peter G. Eames (age 49) |
| Vice President of New Business Development | John K. Myers (age 76) |
Major Backers & Investors (NVEC)
Notable institutional backers of Nve Corp /New/ include Penserra Capital Management LLC, Defiance Etfs, LLC, ETF Series Solutions-Defiance Quantum ETF, according to Nexqual as of July 25, 2026 at 01:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Penserra Capital Management LLC | 12% |
| Defiance Etfs, LLC | 12% |
| ETF Series Solutions-Defiance Quantum ETF | 12% |
| Royce & Associates LP | 4.74% |
| ROYCE FUND-Royce Small-Cap Special Equity Fund | 4.7% |
| Renaissance Technologies | 3.59% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 14.46% |
| BlackRock | 10.07% |
| State Street | 9.3% |
| Geode Capital | 3% |
Source: Nexqual, July 25, 2026 at 01:45 UTC.
From Nve Corp /New/'s Latest SEC 10-K Filing (filed 2026-05-06)
Key Strengths & Strategy (as disclosed to the SEC)
- We protect our proprietary technology and intellectual property by seeking patents, trademarks, and copyrights, and by maintaining trade secrets by entering into confidentiality agreements with employees, suppliers, customers, and prospective customers depending on the circumstances.
- We face various cybersecurity threats, including threats to our information technology infrastructure and attempts to gain access to our proprietary or classified information, and denial-of-service and distributed denial-of-service attacks.
- Also, our confidentiality agreements may not provide meaningful protection of our proprietary information.
- Our inability to maintain our proprietary rights could have a material adverse effect on our business, financial condition, and results of operations. 11 Table of Contents Risks Related to Our Industry   We face an uncertain economic environment in the industries we serve, which could adversely affect our business.
Partnerships
- We have agreements with certain customers, including a Supplier Partnering Agreement, as amended, with Abbott Laboratories, which expires December 31, 2027.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SLSN | Solesence, Inc. | USD 0.94 | ▲ 10.59% |
| VECO | Veeco Instruments Inc. | USD 51.66 | ▼ 5.38% |
| ALTI | AlTi Global, Inc. | USD 3.41 | ▲ 2.1% |
| NGEN | NervGen Pharma Corp. | USD 1.63 | ▼ 5.23% |
| ACCL | Acco Group Holdings Limited | USD 2.13 | ▼ 0.47% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:45 UTC. This page is informational and not investment advice.